Mylan and Biocon launch biosimilar cancer drug Herceptin in the US UU.

New Delhi, December 2 () The important biotechnology company Biocon and medicines Mylan NV announced on Monday the launch of the biosimilar Ogivri, used for the treatment of certain breast and gastric cancers, in the US market.

He is a biosimilar of the Herceptin de Roche, the world's largest pharmacist.

Ogivri is available in a 420 mg multidose vial and a 150 mg single dose vial to provide patients with dosage and treatment flexibility, the companies said in a joint statement.

The US launch of Ogivri, the biosimilar trastuzumab jointly developed by Biocon Biologics and Mylan, marks a significant milestone in our biosimilar journey, said Biocon Biologics executive director Christiane Hamacher.

The introduction of 420 mg multipurpose vials and 150 mg single-use vials of high quality biosimilar trastuzumab with solid long-term efficacy and safety data will offer greater variety and value to patients, prescribers and payers in the US. UU. .

We aim to serve 5 million patients through our biosimilar portfolio and cross a revenue milestone of USD 1 billion for fiscal year 22, Hamacher said.

Ogivri was the first biosimilar trastuzumab approved by the United States Food and Drug Administration (USFDA), according to the statement.

It is approved for all indications of Herceptin, including the treatment of HER2 overexpressing breast cancer and metastatic stomach cancer, he added.

As one of the largest providers of cancer medications in the United States, we are proud to offer Ogivri, biosimilar trastuzumab, in doses of 420 mg and 150 mg and help increase more affordable access to this important treatment option for patients with breast cancer and gastric, said the president of Mylan, Rajiv Malik.

With the regulatory approval of our biosimilar trastuzumab in more than 80 countries worldwide, we are bringing a vast global experience in biosimilars to the US. UU. And we look forward to continuing our work with all stakeholders in the health care system to reduce costs, improve access and advance care. he added.

Ogivri is the second biosimilar offered by Mylan through the Mylan-Biocon Biologics association in the USA. UU. And the second biosimilar approved by the FDA through this collaboration to support cancer patients, according to the statement. Biocon Ltd shares closed at Rs 285.95 per scrip on BSE on Monday, an increase of 1.53 percent since its previous close. AKT RVK

comments